HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INCY
Incyte Corporation
INCY's fundamentals are mixed, but it looks expensive: trading at 65x earnings, about twice its usual 30x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INCY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Strong | |
| Strong |
INCY's revenue, cash flow and balance sheet are currently healthy, and its profitability is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INCY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $122 | — |
| Cheap | 17x | $31.41 | -74% |
| Fair | 30x | $56.29 | -54% |
| Expensive | 64x | $121 | -0.9% |
| Current | 65x | $122 | — |
Historical ranges are pointers, not guarantees.
INCY's PE is in its expensive range at 65x. If earnings grow as analysts expect, today's price would be 16x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INCY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
INCY has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INCY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.78 | +314% |
| Q3 2026 | $1.88 | -68% |
| Q2 2026 | $7.85 | +83% |
| Q1 2026 | $7.08 | +3440% |
| Q4 2025 | $6.41 | +4173% |
| Q3 2025 | $5.85 | +4079% |
| Q2 2025 | $4.28 | +1089% |
| Q1 2025 | $0.20 | -94% |
| Q4 2024 | $0.15 | -94% |
INCY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INCY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over INCY on profitability, with a higher operating margin.
INCY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +14% |
| Q2 2026 | $1.7B | +38% |
| Q1 2026 | $1.3B | +21% |
| Q4 2025 | $1.5B | +28% |
| Q3 2025 | $1.4B | +20% |
| Q2 2025 | $1.2B | +16% |
| Q1 2025 | $1.1B | +20% |
| Q4 2024 | $1.2B | +16% |
INCY's revenue has grown year over year every quarter since late 2020: $1.6B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | -78 points |
| Q2 2026 | 42% | -1.9 points |
| Q1 2026 | 24% | +4.2 points |
| Q4 2025 | 22% | -3.3 points |
| Q3 2025 | 32% | +20 points |
| Q2 2025 | 44% | +89 points |
| Q1 2025 | 19% | +9.1 points |
| Q4 2024 | 26% | +7.1 points |
INCY's operating margin was −45% last quarter, down 78 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
INCY has the stronger cash trend. Its trailing FCF is up 68% versus its history, compared with HIMS at down 84%.
INCY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2024 | $218.8M | +$324.4M |
| Q4 2023 | $147.7M | -44% |
| Q3 2023 | $147.8M | -45% |
| Q2 2023 | $306.5M | +89% |
| Q1 2023 | -$105.6M | -153% |
| Q4 2022 | $262.4M | +224% |
| Q3 2022 | $268.6M | +20% |
| Q2 2022 | $162.4M | +52% |
INCY generated $821M in free cash flow over the past year, up 40% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INCY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INCY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -5M shares |
| 1 year | +0.9% | +1.8M shares |
| 3 years | -10% | -22.9M shares |
| 5 years | -8.5% | -19M shares |
| Available history | -7% | -15.3M shares |
INCY has 203M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $103,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INCY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -7.4x | Net Cash |
| Q4 2024 | -11.2x | Net Cash |
INCY has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INCY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.3 | Neutral |
| Stochastic | 54.3 | Neutral |
INCY's weekly RSI is 58 (neutral) and its Stochastic is 54 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INCY PE vs Healthcare Sector
| Metric | INCY | Sector median | Relative |
|---|---|---|---|
| PE | 65x | 26x | 150% above |
| PE % | 83 | 29 | 54 pts above |
INCY is trading at 65x earnings, a 150% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INCY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $117.8 | 3.3% above |
| 20 week MA | $119.9 | 1.5% above |
| 50 week MA | $107.8 | 13% above |
| 100 week MA | $91.4 | 33% above |
| 200 week MA | $77.7 | 57% above |
INCY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INCY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.4 | $87.4 | -1.2% |
| 2021 | $87.4 | $73.5 | -16% |
| 2022 | $73.5 | $81.4 | +11% |
| 2023 | $81.4 | $62.8 | -23% |
| 2024 | $62.8 | $69.2 | +10% |
| 2025 | $69.2 | $100.1 | +45% |
| 2026 YTD | $100.1 | $121.7 | +22% |
INCY has the edge over HIMS on returns for 2026, with the stronger performance.